logo
Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial
Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections
Phase I Clinical Trial of Valacyclovir and Standard of Care Cyclophosphamide in Children With Endemic Burkitt Lymphoma in Malawi
High Frequencies of Response After Limited Primary Therapy for Multiple Myeloma
Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib
Prognostic Factors Associated With Disease Progression and Overall Survival in Patients With Myelodysplastic Syndromes Treated With Decitabine
Clofarabine Does Not Negatively Impact the Outcomes of Patients With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation
Clinical Prognostic Factors for Survival and Risk of Progression to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndromes With < 10% Marrow Blasts and Non-Unfavorable Cytogenetic Categories
Therapy of Core Binding Factor Acute Myeloid Leukemia: Incremental Improvements Toward Better Long-Term Results
Bortezomib Administration With Severe Hyperbilirubinemia Caused by Hepatic Plasma Cell Infiltration: A Case Report
Desensitization to Lenalidomide in a Patient With Relapsed Multiple Myeloma
Successful Use of Intrathecal Carboxypeptidase G2 for Intrathecal Methotrexate Overdose: A Case Study and Review of the Literature
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Multiple Myeloma in HIV-Positive Patients in the Highly Active Antiretroviral Therapy Era: The Myeloma Institute of Research and Therapy Experience
A Case Report of Chronic Myelogenous Leukemia in a Patient With Multiple Myeloma and a Review of the Literature
Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia
Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenström Macroglobulinemia
Survival in Monoclonal Gammopathy of Undetermined Significance and Waldenström Macroglobulinemia
Familial Predisposition to Monoclonal Gammopathies: Deviations in B-Cell Biology
Etiology of Waldenström Macroglobulinemia: Genetic Factors and Immune-related Conditions
Genomic Abnormalities of Waldenström Macroglobulinemia and Related Low-Grade B-Cell Lymphomas
Genomic Studies Have Identified Multiple Mechanisms of Genetic Changes in Waldenström Macroglobulinemia
microRNA Aberrations in Waldenström Macroglobulinemia
Microarray Demonstrates Different Gene Expression Profiling Signatures Between Waldenström Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance
Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells
Intraclonal Heterogeneity in Concomitant Monoclonal Lymphocyte and Plasma Cell Populations: Combining Flow Cytometric Cell Sorting With Molecular Monoclonality Profiling
The Bone Marrow Microenvironment in Waldenström Macroglobulinemia
Targeting the Toll-like Receptor/Interleukin 1 Receptor Pathway in Human Diseases: Rational Design of MyD88 Inhibitors
Primary Therapy of Waldenström Macroglobulinemia With Nucleoside Analogue–Based Therapy
Fludarabine, Cyclophosphamide, and Rituximab in Salvage Therapy of Waldenström's Macroglobulinemia
Proteasome Inhibitor Therapy for Waldenström's Macroglobulinemia
Role of Plasmapheresis in Waldenström's Macroglobulinemia
Patients With Waldenström Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration
Diagnostic Challenges of Amyloidosis in Waldenström Macroglobulinemia
Challenges With Serum Protein Electrophoresis in Assessing Progression and Clinical Response in Patients With Waldenström Macroglobulinemia
Comparative Response Assessment by Serum Immunoglobulin M M-Protein and Total Serum Immunoglobulin M After Treatment of Patients With Waldenström Macroglobulinemia